Pfizer Inc. is a strong wide moat stock, discussing drug pricing reduction with the Trump administration. Uncertainty remains on how the US government will implement the policy. Pfizer CEO highlighted potential consequences on drug pricing due to US pressure on European nations.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing